See more : Neuren Pharmaceuticals Limited (NEU.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Enfusion, Inc. (ENFN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enfusion, Inc., a leading company in the Software – Application industry within the Technology sector.
- Element 25 Limited (ELMTF) Income Statement Analysis – Financial Results
- Torrent Power Limited (TORNTPOWER.NS) Income Statement Analysis – Financial Results
- QIWI plc (QIWI) Income Statement Analysis – Financial Results
- Saurashtra Cement Limited (SAURASHCEM.BO) Income Statement Analysis – Financial Results
- Chang Hwa Commercial Bank, Ltd. (2801.TW) Income Statement Analysis – Financial Results
Enfusion, Inc. (ENFN)
About Enfusion, Inc.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 174.54M | 150.35M | 111.70M | 79.57M | 59.03M |
| Cost of Revenue | 57.64M | 47.10M | 31.85M | 21.36M | 16.96M |
| Gross Profit | 116.89M | 103.25M | 79.86M | 58.21M | 42.07M |
| Gross Profit Ratio | 66.97% | 68.67% | 71.49% | 73.16% | 71.27% |
| Research & Development | 19.89M | 17.16M | 153.40M | 6.32M | 4.15M |
| General & Administrative | 64.64M | 68.76M | 150.61M | 35.89M | 16.63M |
| Selling & Marketing | 20.42M | 29.29M | 51.73M | 9.93M | 7.43M |
| SG&A | 85.05M | 98.05M | 202.34M | 45.82M | 24.05M |
| Other Expenses | 0.00 | -638.00K | -1.19M | 82.00K | -3.00K |
| Operating Expenses | 104.95M | 115.21M | 355.74M | 52.13M | 28.20M |
| Cost & Expenses | 162.59M | 162.31M | 387.58M | 73.49M | 45.16M |
| Interest Income | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
| Interest Expense | 0.00 | 413.00K | 4.59M | 1.66M | 724.00K |
| Depreciation & Amortization | 9.99M | 6.60M | 3.98M | 2.29M | 1.16M |
| EBITDA | 21.94M | -5.62M | -271.91M | 8.37M | 15.02M |
| EBITDA Ratio | 12.57% | -3.74% | -244.49% | 10.62% | 25.45% |
| Operating Income | 11.95M | -11.96M | -275.88M | 6.07M | 13.87M |
| Operating Income Ratio | 6.85% | -7.96% | -246.99% | 7.63% | 23.50% |
| Total Other Income/Expenses | -464.00K | -225.00K | -5.78M | -1.58M | -727.00K |
| Income Before Tax | 11.48M | -12.19M | -281.66M | 4.49M | 13.14M |
| Income Before Tax Ratio | 6.58% | -8.11% | -252.16% | 5.65% | 22.26% |
| Income Tax Expense | 2.23M | 1.07M | 579.00K | 433.00K | 486.00K |
| Net Income | 6.03M | -13.26M | -282.24M | 4.06M | 12.66M |
| Net Income Ratio | 3.45% | -8.82% | -252.68% | 5.10% | 21.44% |
| EPS | 0.10 | -0.16 | -4.30 | 0.04 | 0.11 |
| EPS Diluted | 0.07 | -0.16 | -4.30 | 0.04 | 0.11 |
| Weighted Avg Shares Out | 88.20M | 85.39M | 65.58M | 113.05M | 113.05M |
| Weighted Avg Shares Out (Dil) | 129.43M | 85.39M | 65.58M | 113.05M | 113.05M |
Enfusion To Present at Upcoming Investor Events
Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript
Here's What Key Metrics Tell Us About Enfusion (ENFN) Q3 Earnings
Enfusion, Inc. (ENFN) Q3 Earnings and Revenues Miss Estimates
Enfusion Announces Third Quarter 2024 Results
Enfusion Announces Key Leadership Team Additions to Drive Client Success and Fuel Innovation
Enfusion Announces Date of Third Quarter 2024 Results
The Schall Law Firm Invites Investor Participation In An Inquiry Into Enfusion Inc For Violating Securities Laws
Enfusion, Inc. Is Being Looked Into For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Investors To Help Investigate Whether Enfusion Inc Violated Securities Laws
Source: https://incomestatements.info
Category: Stock Reports